EUCTR2019-001074-29-ES进行中（未招募）1 期
An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in preceding studies with LOU064
ovartis Farmacéutica, S.A.0 个研究点目标入组 229 人开始时间: 2023年10月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 229
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Written informed consent must be obtained before any assessment is performed.
- •- Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules.
- •- Subjects rolling over from CLOU064A2201 must have completed the Week 12 visit (end of treatment period) or the Week 16 visit (end of the follow-up period) and will be allocated to the treatment period or the observational period of CLOU064A2201E1 based on the UAS7 score (of the 7 days prior to the respective visit) as follows:
- •a) Subjects rolling over at Week 12 of CLOU064A2201 with a UAS7=16 will be allocated to the Treatment period (note: subjects with UAS7<16 at Week 12 are not eligible to rollover into CLOU064A2201E1 but need to enter the follow-up period of CLOU064A2201).
- •b) Subjects rolling over at Week 16 of CLOU064A2201 with a UAS7=16 will be allocated to the Treatment period.
- •c) Subjects rolling over at Week 16 of CLOU064A2201 with a UAS7<16 will be allocated to the Observational period.
- •- Rollover criteria for subjects with CSU from other, not-yet specified studies with LOU064 will be detailed in the protocols of these studies.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 230
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days (for small molecules) prior to enrollment or until the expected pharmacodynamic (PD) effect has returned to baseline (for biologics), whichever is longer; or longer if required by local regulations.
- •- History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.
- •- Subjects having a clearly defined, predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact urticaria
- •- Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria, or acquired/drug-induced urticaria
- •- Any other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results, eg atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
- •- History or current diagnosis of ECG abnormalities indicating significant risk of safety for subjects participating in the study
- •- Patients/subjects taking medications prohibited by the protocol
- •- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- •- Pregnant or nursing (lactating) women
- •- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 7 days after stopping study medication.
- •- Sexually active males must use a condom during intercourse while taking drug and for 7 days after stopping study medication and should not father a child in this period. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above.
- •- Major surgery within 8 weeks prior to enrollment or surgery planned prior to end of the treatment period.
- •- History of live attenuated vaccine within 6 weeks prior to enrollment or requirement to receive these vaccinations at any time during study drug treatment
- •- Evidence of clinically significant cardiac, neurologic, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participant participation.
- •- Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids.
- •- Hematology parameters at last visit before Day 1 of the Treatment period (either last available value from CLOU064A2201 or most recent value taken during observational period): Hemoglobin: < 10 g/dl; Platelets: < 100 000/mm3; White blood cells: < 3 000/mm3; Neutrophils: < 1 500/mm3;
- •- Significant bleeding risk or coagulation disorders
- •- History of gastrointestinal bleeding, eg in association with use of Nonster
研究者
相似试验
进行中（未招募）
1 期
An open-label extension study to evaluate the long-term safety and tolerability of LOU064 in subjects with CSEUCTR2019-001074-29-HUovartis Pharma AG250
进行中（未招募）
1 期
An open-label extension study to evaluate the long-term safety and tolerability of LOU064 in subjects with CSChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-001074-29-SKovartis Pharma AG250
进行中（未招募）
1 期
An open-label extension study to evaluate the long-term safety and tolerability of LOU064 in subjects with CSEUCTR2019-001074-29-GBovartis Pharma AG250
进行中（未招募）
1 期
An open-label extension study to evaluate the long-term safety and tolerability of LOU064 in subjects with CSChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-001074-29-FRovartis Pharma AG250
已完成
2 期
An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in CLOU064A2201chronic spontaneous urticariaJPRN-jRCT2031210538Takamitsu Hirano45